Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics

Natera, Inc. (NASDAQ:NTRA) is one of the best hot large cap stocks to buy according to hedge funds. On August 29, Natera, Inc. (NASDAQ:NTRA) provided an update on its intellectual property litigation with NeoGenomics, Inc., announcing that the US District Court for the Middle District of North Carolina issued a ruling “invalidating certain claims in two patents that Natera asserted against NeoGenomics’ v1.1 RaDaR test.”

Management stated that the company is looking into its options, including an appeal and further enforcement with other patents.

Natera, Inc. (NASDAQ:NTRA) holds a comprehensive portfolio of over 500 issued or pending patents across the globe, and is committed to the protection of its significant investments in innovation.

Natera, Inc. (NASDAQ:NTRA) is a diagnostics company that develops and commercializes molecular testing services, applying its technological services in oncology, women’s health, and organ health.

The company provides various diagnostic tests, including Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC), and non-invasive paternity testing (PAT).

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.